An Engineered Nanoplatform with Tropism Toward Irradiated Glioblastoma Augments Its Radioimmunotherapy Efficacy
Advanced Materials · 2024-08 · 36 (32)
DOI: 10.1002/adma.202314197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 08.06.2024. Verfasst von Zheng Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Nano-Bio Interface, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, S…. Hauptthemen laut MEDLINE: Glioblastoma, Radioimmunotherapy, Nanoparticles. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Suzhou Basic Research Pilot Project.
Abstract (Originalsprache)
Combining radiotherapy with immune checkpoint blockade therapy offers a promising approach to treat glioblastoma multiforme (GBM), yet challenges such as limited effectiveness and immune‐related adverse events (irAEs) persist. These issues are largely due to the failure in targeting immunomodulators directly to the tumor microenvironment. To address this, a biomimetic nanoplatform that combines a genetically modified mesenchymal stem cell (MSC) membrane with a bioactive nanoparticle core for chemokine‐directed radioimmunotherapy of GBM is developed. The CC chemokine receptor 2 (CCR2)‐overexpressing MSC membrane acts as a tactical tentacle to achieve radiation‐induced tropism toward the abundant chemokine (CC motif) ligand 2 (CCL2) in irradiated gliomas. The nanoparticle core, comprising diselenide‐bridged mesoporous silica nanoparticles (MSNs) and PD‐L1 antibodies (αPD‐L1), enables X‐ray‐responsive drug release and radiosensitization. In two murine models with orthotopic GBM tumors, this nanoplatform reinvigorated immunogenic cell death, and augmented the efficacy and specificity of GBM radioimmunotherapy, with reduced occurrence of irAEs. This study suggests a promising radiation‐induced tropism strategy for targeted drug delivery, and presents a potent nanoplatform that enhances the efficacy and safety of radio‐immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory of Nano-Bio Interface, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China.
- National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, Guangdong, 510006, China.
- School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, Guangdong, 510006, China.
- School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China.
- Department of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.
ORCID-Profile: Kam W Leong
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Suzhou Basic Research Pilot Project
- the Science and Technology Foundation of Suzhou
Zitieren
APA
Wang, Z., Chen, F., Cao, Y., Zhang, F., Sun, L., Yang, C., Xie, X., Wu, Z., Sun, M., Ma, F., Shao, D., Leong, K. W., & Pei, R. (2024). An Engineered Nanoplatform with Tropism Toward Irradiated Glioblastoma Augments Its Radioimmunotherapy Efficacy. Advanced Materials, 36(32). https://doi.org/10.1002/adma.202314197
Vancouver
Wang Z, Chen F, Cao Y, Zhang F, Sun L, Yang C, et al. An Engineered Nanoplatform with Tropism Toward Irradiated Glioblastoma Augments Its Radioimmunotherapy Efficacy. Advanced Materials. 2024;36(32). doi:10.1002/adma.202314197
BibTeX
@article{Wang2024,
author = {Wang, Zheng and Chen, Fangman and Cao, Yi and Zhang, Fan and Sun, Lina and Yang, Chao and Xie, Xiaochun and Wu, Ziping and Sun, Madi and Ma, Fanshu and Shao, Dan and Leong, Kam W and Pei, Renjun},
title = {An Engineered Nanoplatform with Tropism Toward Irradiated Glioblastoma Augments Its Radioimmunotherapy Efficacy},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {32},
doi = {10.1002/adma.202314197}
}
EUVIMED